If you’ve been scouring headlines trying to work out if you “qualify” take a breath. Here’s the real story behind NHS access to Mounjaro.
New NHS Criteria (2025 Phase 1):
- BMI ≥ 40 (or ≥ 37.5 for high-risk ethnicities)
- At least 4 co-existing health conditions directly linked to obesity (MHRA/NICE TA875)
- Referral to a Tier 3 weight management clinic
This is not yet available via every pharmacy. It’s limited, and tightly regulated. Only patients with significant clinical vulnerability are being considered in this first rollout.
Why Mounjaro Is Being Prioritised
- Targets both GLP-1 and GIP, two key hunger/satiety pathways
- Lowers systemic inflammation and fatty liver burden
- Improves insulin signalling, blood sugar control, and cardiovascular markers
Golden Nugget: Mounjaro’s metabolic benefits extend beyond weight loss. It can lower triglycerides, reduce ALT (a liver enzyme linked to NAFLD), and support dopamine pathways critical for food-related reward systems.
The Functional Medicine Difference
At our clinic, we integrate medication into a broader picture:
- Gut microbiome analysis to improve nutrient absorption and hormone detox
- Cortisol and sleep tracking for leptin/ghrelin balance
- Precision nutrition and trauma-informed coaching
You deserve more than a jab. You deserve to understand why your body stores weight and how to work with it, not against it.
